Ascendis Pharma A/s
Clinical trials sponsored by Ascendis Pharma A/s, explained in plain language.
-
Weekly shot could replace daily injections for kids with growth disorders
Disease control Recruiting nowThis study is testing if a new, once-weekly growth hormone injection works as well as the current standard of daily injections for children with certain conditions that cause short stature. About 186 children and teens with Turner syndrome, SHOX deficiency, being born small, or u…
Phase: PHASE3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for babies with dwarfism: weekly shot aims to boost growth
Disease control Recruiting nowThis study is testing a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, a genetic condition that causes short stature. The main goals are to see if the treatment is safe and if it helps children grow taller over 52 weeks. Infants will be ran…
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New weekly shot aims to boost growth in teens with dwarfism
Disease control Recruiting nowThis trial is testing whether a new weekly injection called navepegritide can safely increase the annual growth rate in adolescents (ages 12-18) with achondroplasia, a genetic condition that causes dwarfism. About 24 participants will receive either the active drug or a placebo (…
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Tracking babies born to moms on rare disease drug
Knowledge-focused Recruiting nowThis study aims to gather safety information about the drug YORVIPATH during pregnancy and breastfeeding. It will follow about 50 women with hypoparathyroidism who took the drug around the time of pregnancy. Researchers will collect data on pregnancy complications, birth outcomes…
Sponsor: Ascendis Pharma A/S • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC